Publications by authors named "Samantha Jaglowski"

69Publications

A New Standard in Graft-versus-Host Disease Prophylaxis? An Introduction to Blood and Marrow Transplant Clinical Trials Network 1703.

Biol Blood Marrow Transplant 2020 Sep 10. Epub 2020 Sep 10.

Department of Hematology/Oncology, Mayo Clinic College of Medicine, Phoenix, Arizona. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.08.029DOI Listing
September 2020

Second cancer incidence in CLL patients receiving BTK inhibitors.

Leukemia 2020 Jul 23. Epub 2020 Jul 23.

Department of Internal Medicine, Division of Hematology, Arthur G James Comprehensive Cancer Center, The Ohio State University Wexner Medical Center, Columbus, OH, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-020-0987-6DOI Listing
July 2020

Addressing the Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Hematopoietic Cell Transplantation: Learning Networks as a Means for Sharing Best Practices.

Biol Blood Marrow Transplant 2020 07 24;26(7):e147-e160. Epub 2020 Apr 24.

Host Defense Program, Division of Infectious Diseases, Nationwide Children's Hospital, Columbus, Ohio; Department of Pediatrics, The Ohio University College of Medicine, Columbus, Ohio; The Ohio State University Comprehensive Cancer Center, Columbus, Ohio; Blood and Marrow Transplant Program, Division of Hematology/Oncology/BMT, Nationwide Children's Hospital, Columbus, Ohio. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.04.018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7194714PMC
July 2020

Fluoroquinolone Prophylaxis in Autologous Stem Cell Transplantation: Worthy of a Second Look.

Biol Blood Marrow Transplant 2020 Aug 15;26(8):e198-e201. Epub 2020 Apr 15.

Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.03.027DOI Listing
August 2020

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.

N Engl J Med 2020 04;382(14):1331-1342

From the University of Texas M.D. Anderson Cancer Center, Houston (M.W.), and Texas Oncology, Dallas (H.H.); Banner M.D. Anderson Cancer Center, Gilbert, AZ (J.M.); John Theurer Cancer Center, Hackensack, NJ (A.G.); Moffitt Cancer Center, Tampa (F.L.L.), and the University of Miami, Miami (A.B.) - both in Florida; Dana-Farber Cancer Institute, Boston (C.A.J.); Cleveland Clinic Foundation, Cleveland (B.T.H.), and the Ohio State University Comprehensive Cancer Center, Columbus (S.J.); David Geffen School of Medicine at UCLA, Los Angeles (J.M.T.), Stanford University School of Medicine, Stanford (D.B.M.), and Kite, a Gilead company, Santa Monica (W.P., L.Z., J.M.R., R.K.J., A.V.R.) - all in California; Sarah Cannon Research Institute-Tennessee Oncology, Nashville (I.W.F.); Colorado Blood Cancer Institute, Denver (P.A.M.); Swedish Cancer Institute, Seattle (J.M.P.); the Academic Medical Center, University of Amsterdam, Amsterdam, for the Lunenburg Lymphoma Phase I/II Consortium (M.-J.K.); Centre Hospitalier Universitaire (CHU) Bordeaux, Service d'Hematologie et Therapie Cellulaire, Bordeaux (N.M.), and CHU Rennes, INSERM French Blood Establishment, Rennes (R.H.) - both in France; Fox Chase Cancer Center, Philadelphia (H.F.); Universitätsklinikum Würzburg, Würzburg, Germany (M.S.T.); and the University of Rochester Medical Center, Rochester, NY (P.M.R.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1914347DOI Listing
April 2020

Carfilzomib for Treatment of Refractory Chronic Graft-versus-Host Disease: A Chronic GVHD Consortium Pilot Phase II Trial.

Biol Blood Marrow Transplant 2020 02 6;26(2):278-284. Epub 2019 Sep 6.

Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.09.002DOI Listing
February 2020

Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study.

Biol Blood Marrow Transplant 2019 10 28;25(10):2002-2007. Epub 2019 Jun 28.

Division of Hematology, Department of Internal Medicine, The Ohio State University Medical Center, Columbus, Ohio.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.06.023DOI Listing
October 2019

Comparison of Two Doses of Antithymocyte Globulin in Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation.

Biol Blood Marrow Transplant 2019 10 20;25(10):1993-2001. Epub 2019 Jun 20.

Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.06.014DOI Listing
October 2019

Have We Achieved a Goldilocks Grade of Graft-Versus-Host Disease?

Biol Blood Marrow Transplant 2019 06 17;25(6):e189-e190. Epub 2019 Apr 17.

Division of Hematology, The Ohio State University, Columbus, Ohio.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.04.009DOI Listing
June 2019

Running the tank to empty: how far can the CAR go?

Blood 2019 04;133(15):1617-1618

The Ohio State University.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/lookup/doi/10.1182/blood-2019-02
Publisher Site
http://dx.doi.org/10.1182/blood-2019-02-900761DOI Listing
April 2019

Tocilizumab as first-line therapy for steroid-refractory acute graft-versus-host-disease: analysis of a single-center experience.

Leuk Lymphoma 2019 09 15;60(9):2223-2229. Epub 2019 Feb 15.

Department of Pharmacy, The James Cancer Hospital, The Ohio State University Comprehensive Cancer Center , Columbus , Ohio , 43210 , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1573996DOI Listing
September 2019

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

N Engl J Med 2019 01 1;380(1):45-56. Epub 2018 Dec 1.

From the Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia (S.J.S.); the Hematopoietic Cellular Therapy Program, University of Chicago Medicine, Chicago (M.R.B.); Peter MacCallum Cancer Centre, St. Vincent's Hospital and University of Melbourne, Melbourne, VIC (C.S.T.), and the Royal Prince Alfred Hospital and Department of Medicine, University of Sydney, Sydney (P.J.H.) - both in Australia; Winship Cancer Institute of Emory University, Bone Marrow and Stem Cell Transplant Center, Atlanta (E.K.W.); the Department of Hematology and Oncology, University Hospital of Cologne, Cologne (P.B.), and the Würzburg University Medical Center, Center for Allogeneic Stem Cell Transplantation, Würzburg (S.M.) - both in Germany; the Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Cancer Center, Kansas City (J.P.M.); the Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna (U.J.); James Cancer Hospital and Solove Research Institute, Ohio State University Comprehensive Cancer Center, Columbus (S.J.); the Department of Hematology and Blood and Marrow Transplant, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco (C.A.); the Department of Lymphoma and Myeloma, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston (J.R.W.); Maisonneuve-Rosemont Hospital, University of Montreal, Montreal (I.F.), and the Juravinski Hospital and Cancer Centre, McMaster University, Hamilton, ON (S.R.F.) - both in Canada; the Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis (V.B.); Karolinska Institutet and University Hospital, Department of Laboratory Medicine/Department of Cell Therapy and Allogeneic Stem Cell Transplantation, Stockholm (S.M.); University of Michigan Comprehensive Cancer Center, Ann Arbor (J.M.M.); the Department of Oncology, Oslo University Hospital, Oslo (H.H.); Novartis Pharma, Basel, Switzerland (S.P., O.A.); Novartis Pharmaceuticals (L.B.P., J.C.) and Novartis Institutes for BioMedical Research (R.A.), East Hanover, NJ; the Department of Hematology, Hospices Civils de Lyon, Université de Lyon, Lyon, France (G.S.); and the Center for Hematologic Malignancies, Oregon Health and Science University Knight Cancer Institute, Portland (R.T.M.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1804980
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1804980DOI Listing
January 2019

How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD.

Blood Adv 2018 08;2(15):2012-2019

Division of Blood and Marrow Transplantation, Department of Pediatrics, The University of Minnesota, Minneapolis, MN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2018013060DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6093735PMC
August 2018

Road trip to remission with CARs.

Blood 2017 11;130(21):2240

THE OHIO STATE UNIVERSITY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2017-10-808584DOI Listing
November 2017

Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma.

Biol Blood Marrow Transplant 2018 01 13;24(1):78-85. Epub 2017 Oct 13.

Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin; Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2017.10.011DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5743624PMC
January 2018

The regulation of tumor-suppressive microRNA, miR-126, in chronic lymphocytic leukemia.

Cancer Med 2017 Apr 15;6(4):778-787. Epub 2017 Mar 15.

Division of Hematology, Department of Internal Medicine and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.996DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5387133PMC
April 2017

A phase 2 trial of alisertib in patients with relapsed or refractory B-cellnon-Hodgkin lymphoma.

Leuk Lymphoma 2017 09 20;58(9):1-2. Epub 2017 Feb 20.

b Division of Hematology , The Ohio State University James Comprehensive Cancer Center , Columbus , OH , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2017.1289527DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5497734PMC
September 2017

Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis.

J Clin Oncol 2016 09 6;34(26):3141-9. Epub 2016 Jun 6.

Nilanjan Ghosh, Levine Cancer Institute, Carolinas Healthcare System, Charlotte, NC; Reem Karmali, Rush University Medical Center; Sonali M. Smith, The University of Chicago, Chicago, IL; Vanderson Rocha, Churchill Hospital, Oxford, United Kingdom; Kwang Woo Ahn, Alyssa DiGilio, and Mehdi Hamadani, Medical College of Wisconsin & Center for International Blood and Marrow Transplant Research; Parameswaran N. Hari and Anita D'Souza, Medical College of Wisconsin; Timothy S. Fenske, Froedtert Memorial Lutheran Hospital, Milwaukee, WI; Veronika Bachanova, University of Minnesota Medical Center, Minneapolis, MN; Ulrike Bacher, University Medicine Goettingen and University Cancer Center Hamburg, Hamburg, Germany; Parastoo Dahi, Memorial Sloan Kettering Cancer Center-Adults, New York, NY; Marcos de Lima, University Hospitals Case Medical Center, Cleveland; Samantha Jaglowski, The Ohio State University Medical Center, Columbus, OH; Siddhartha Ganguly, University of Kansas Medical Center, Kansas City, KS; Mohamed A. Kharfan-Dabaja, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Tim D. Prestidge, Blood and Cancer Centre, Starship Children's Hospital, Auckland, New Zealand; Bipin N. Savani, Vanderbilt University Medical Center, Nashville, TN; Anna M. Sureda, European Group for Blood and Marrow Transplantation and Hospital Duran I Reynals, Barcelona, Spain; Edmund K. Waller, Winship Cancer Institute, Emory University, Atlanta, GA; Alex F. Herrera, City of Hope National Medical Center, Duarte, CA; Philippe Armand, Dana-Farber Cancer Institute, Boston, MA; Rachel B. Salit, Fred Hutchinson Cancer Research Center, Seattle, WA; and Nina D. Wagner-Johnston, Ephraim Fuchs, and Javier Bolaños-Meade, Johns Hopkins University Sidney Kimmel Cancer Center, Baltimore, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.66.3476DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5012706PMC
September 2016

Ibrutinib for treatment of chronic lymphocytic leukemia.

Am J Health Syst Pharm 2016 Mar;73(6):367-75

Division of Hematology, Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Solove Research Institute, Columbus, OH.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2146/ajhp140760DOI Listing
March 2016

Tocilizumab for steroid refractory acute graft-versus-host disease.

Leuk Lymphoma 2016 3;57(1):81-5. Epub 2015 Jul 3.

b Division of Hematology, Department of Internal Medicine , James Cancer Hospital, The Ohio State University Comprehensive Cancer Center , Columbus , Ohio , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2015.1045896DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4698359PMC
October 2016

Transplant for CLL: still an option?

Blood 2014 Dec;124(26):3835-6

THE OHIO STATE UNIVERSITY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2014-10-606871DOI Listing
December 2014

Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.

N Engl J Med 2014 Jun 28;370(24):2286-94. Epub 2014 May 28.

From the Division of Hematology, Department of Internal Medicine (J.A.W., T.-M.L., A.S.R., S.M.J., K.A.B., A.L., A.J.J., J.C. Byrd), the Department of Biomedical Informatics (H.G.O., A.S.Y.), and the Department of Pathology (G.L.), Ohio State University, Columbus; the Department of Medicine, Division of Hematology-Oncology, Weill Cornell Medical College, New York (R.R.F.); the Division of Molecular Genetics, German Cancer Research Center, Heidelberg (M.Z., P.L.), and the Department of Internal Medicine III, University of Ulm, Ulm (S.S.) - both in Germany; Pharmacyclics, Sunnyvale, CA (L.X., D.H.-H.L., S.M.S., D.F.J., J.J.B., B.Y.C.); the Duke Cancer Institute, Duke University, Durham, NC (S.S.D., J.Z.); the Division of Hematology-Oncology, Department of Medicine, Hofstra North Shore-LIJ School of Medicine, New Hyde Park, NY (J.C. Barrientos); and Janssen Research and Development, Beerse, Belgium (M.V.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1400029DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4144824PMC
June 2014

Impact of age on quality of life, functional status, and survival in patients with chronic graft-versus-host disease.

Biol Blood Marrow Transplant 2014 Sep 9;20(9):1341-8. Epub 2014 May 9.

Division of Bone Marrow Transplantation, Massachusetts General Hospital Cancer Center, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2014.05.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4127362PMC
September 2014

Graft-versus-host disease: why have we not made more progress?

Curr Opin Hematol 2014 Mar;21(2):141-7

Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOH.0000000000000026DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4131840PMC
March 2014

Novel therapies and their integration into allogeneic stem cell transplant for chronic lymphocytic leukemia.

Biol Blood Marrow Transplant 2012 Jan;18(1 Suppl):S132-8

Department of Internal Medicine, Division of Hematology and Oncology, Comprehensive Cancer Center at The Ohio State University, Columbus, Ohio, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2011.11.018DOI Listing
January 2012

Choosing first-line therapy for chronic lymphocytic leukemia.

Expert Rev Anticancer Ther 2011 Sep;11(9):1379-90

Division of Hematology, Ohio State University, A352 Starling-Loving Hall, 320 West 10th Avenue, Columbus, OH 43210, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/era.11.132DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4341916PMC
September 2011

The clinical application of monoclonal antibodies in chronic lymphocytic leukemia.

Blood 2010 Nov 7;116(19):3705-14. Epub 2010 Jul 7.

Division of Hematology-Oncology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/cgi/doi/10.1182/blood-2010-04-00
Publisher Site
http://dx.doi.org/10.1182/blood-2010-04-001230DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2981531PMC
November 2010

Rituximab in chronic lymphocytic leukemia.

Semin Hematol 2010 Apr;47(2):156-69

Division of Hematology-Oncology, Department of Medicine, The Ohio State University, Columbus, OH.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminhematol.2010.01.005DOI Listing
April 2010

Lovenox hurts.

Ann Intern Med 2009 Oct;151(8):585-6

The Ohio State University, Columbus, OH 43210, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7326/0003-4819-151-8-200910200-00015DOI Listing
October 2009

Lymphoma in adolescents and young adults.

Semin Oncol 2009 Oct;36(5):381-418

Department of Hematology, The Ohio State University, Columbus, OH, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2009.07.009DOI Listing
October 2009